Retapamulin indications and usage: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Indications and Usage== | ==Indications and Usage== | ||
ALTABAX® is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes[see Clinical Studies (14)]. | ALTABAX® is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to [[Staphylococcus aureus]] (methicillin-susceptible isolates only) or Streptococcus pyogenes[see Clinical Studies (14)]. | ||
Safety in patients younger than 9 months has not been established. | Safety in patients younger than 9 months has not been established. | ||
Revision as of 04:36, 12 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
ALTABAX® is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes[see Clinical Studies (14)].
Safety in patients younger than 9 months has not been established.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ALTABAX and other antibacterial drugs, ALTABAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.[1]
References
Adapted from the FDA Package Insert.